Targeting the glutamatergic system to treat major depressive disorder: Rationale and progress to date

Drugs

Volumn 72, Issue 10, 2012, Pages 1313-1333

  Mathews, Daniel C ^a   Henter, Ioline D ^a   Zarate, Carlos A ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Amantadine; Glutamates; Ketamine; Major depressive disorder; Memantine; Mood disorders; N methyl D aspartate receptor targets; Riluzole; Traxoprodil

Indexed keywords

6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; AMANTADINE; AMPA RECEPTOR AGONIST; ANIRACETAM; ANTIDEPRESSANT AGENT; AZD 6765; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLINE; CREATINE; CYCLOTHIAZIDE; GLUTAMIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KETAMINE; LAMOTRIGINE; LY 451616; MAMMALIAN TARGET OF RAPAMYCIN; MEMANTINE; MK 0657; N ACETYLASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N [2 [4 (3 THIENYL)PHENYL]PROPYL] 2 PROPANESULFONAMIDE; N [2 [4 (4 CYANOPHENYL)PHENYL]PROPYL] 2 PROPANESULFONAMIDE; PIRACETAM; PLACEBO; PROTEIN KINASE B; REMACEMIDE; RILUZOLE; TRAXOPRODIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTERIOR CINGULATE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BIPOLAR DEPRESSION; DISSOCIATIVE DISORDER; DRUG EFFICACY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MAGNETOENCEPHALOGRAPHY; MAJOR DEPRESSION; NEUROBIOLOGY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; SINGLE DRUG DOSE; XEROSTOMIA;

EID: 84863203834     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11633130-000000000-00000     Document Type: Article

References (229)

1. Cole JO. Therapeutic efficacy of antidepressant drugs: a review. JAMA 1964; 190: 448-55
2. Davis JM. Efficacy of tranquilizing and antidepressant drugs. Arch Gen Psychiatry 1965; 13 (6): 552-72
3. Jensen K. Depressions in patients treated with reserpine for arterial hypertension. Acta Psychiatr Neurol Scand 1959; 34 (2): 195-204
4. Bunney Jr WE, Davis JM. Norepinephrine in depressive reactions: a review. Arch Gen Psychiatry 1965; 13 (6): 483-94
5. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122 (5): 509-22
6. Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011; 71 (1): 43-64
7. Schechter LE, Ring RH, Beyer CE, et al. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx 2005; 2 (4): 590-611 (Pubitemid 41393268)
8. Murray CJ, Lopez AD. Evidence-based health policy: lessons from the Global Burden of Disease Study. Science 1996; 274 (5288): 740-3 (Pubitemid 26398244)
9. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163 (1): 28-40 (Pubitemid 43050100)
10. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5 (2): e45
11. Horder J, Matthews P, Waldmann R. Placebo, prozac and PLoS: significant lessons for psychopharmacology. J Psychopharmacol 2011; 25 (10): 1277-88
12. Fountoulakis KN, Moller HJ. Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 2011; 14 (3): 405-12
13. Gueorguieva R, Mallinckrodt C, Krystal JH. Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses. Arch Gen Psychiatry 2011; 68 (12): 1227-37
14. Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990; 185 (1): 1-10 (Pubitemid 20254891)
15. Skolnick P, Layer RT, Popik P, et al. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 1996; 29 (1): 23-6 (Pubitemid 26072654)
16. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47 (4): 351-4 (Pubitemid 30109248)
17. Zarate Jr CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatmentresistant major depression. Arch Gen Psychiatry 2006; 63 (8): 856-64 (Pubitemid 44188478)
18. Machado-Vieira R, Salvadore G, Luckenbaugh DA, et al. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry 2008; 69 (6): 946-58 (Pubitemid 351944948)
19. Watkins JC, Jane DE. The glutamate story. Br J Pharmacol 2006; 147 Suppl. 1: S100-8 (Pubitemid 43077267)
20. Evans RH, Francis AA, Hunt K, et al. Antagonism of excitatory amino acid-induced responses and of synaptic excitation in the isolated spinal cord of the frog. Br J Pharmacol 1979; 67 (4): 591-603 (Pubitemid 10129086)
21. Verkhratsky A, Kirchhoff F. Glutamate-mediated neuronal-glial transmission. J Anat 2007; 210 (6): 651-60 (Pubitemid 46851000)
22. Mathew SJ, Keegan K, Smith L. Glutamate modulators as novel interventions for mood disorders. Rev Bras Psiquiatr 2005; 27 (3): 243-8 (Pubitemid 41337491)
23. Malenka RC, Nicoll RA. Long-term potentiation: a decade of progress? Science 1999; 285 (5435): 1870-4
24. Parsons CG, Danysz W, Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 1998; 11 (9): 523-9
25. Francis PT. Glutamatergic systems in Alzheimer's disease. Int J Geriatr Psychiatry 2003; 18 Suppl. 1: S15-21 (Pubitemid 37150474)
26. Cortese BM, Phan KL. The role of glutamate in anxiety and related disorders. CNS Spectr 2005; 10 (10): 820-30 (Pubitemid 41531936)
27. Fan MM, Raymond LA. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol 2007; 81 (5-6): 272-93 (Pubitemid 46528641)
28. Schoepp DD. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 2001; 299 (1): 12-20 (Pubitemid 32905113)
29. Kim JS, Schmid-Burgk W, Claus D, et al. Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr 1982; 232 (4): 299-304 (Pubitemid 13124834)
30. Altamura CA, Mauri MC, Ferrara A, et al. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 1993; 150 (11): 1731-3 (Pubitemid 23325960)
31. Altamura CA, Mauri MC, Ferrara A, et al. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 1998; 37 (3): 124-9 (Pubitemid 28171767)
32. Mitani H, Shirayama Y, Yamada T, et al. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30 (6): 1155-8 (Pubitemid 43928219)
33. Levine J, Panchalingam K, Rapoport A, et al. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry 2000; 47 (7): 586-93 (Pubitemid 30169251)
34. Frye MA, Tsai GE, Huggins T, et al. Low cerebrospinal fluid glutamate and glycine in refractory affective disorder [published erratum appears in Biol Psychiatry 2007; 61 (10): 1221]. Biol Psychiatry 2007; 61 (2): 162-6 (Pubitemid 46072777)
35. Francis PT, Poynton A, Lowe SL, et al. Brain amino acid concentrations and Ca2+-dependent release in intractable depression assessed antemortem. Brain Res 1989; 494 (2): 315-24 (Pubitemid 19194545)
36. Nowak G, Ordway GA, Paul IA. Alterations in the Nmethyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 1995; 675 (1-2): 157-64
37. Holemans S, De Paermentier F, Horton RW, et al. NMDA glutamatergic receptors, labelled with [3H]MK-801, in brain samples from drug-free depressed suicides. Brain Res 1993; 616 (1-2): 138-43 (Pubitemid 23200040)
38. Altamura C, Maes M, Dai J, et al. Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur Neuropsychopharmacol 1995; 5 Suppl.: 71-5 (Pubitemid 26017262)
39. Maes M, Verkerk R, Vandoolaeghe E, et al. Serumlevels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand 1998; 97 (4): 302-8 (Pubitemid 28179268)
40. Frye MA, Watzl J, Banakar S, et al. Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression. Neuropsychopharmacology 2007; 32 (12): 2490-9 (Pubitemid 350126840)
41. Hasler G, van der Veen JW, et al. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2007; 64 (2): 193-200 (Pubitemid 46220776)
42. Sanacora G, Gueorguieva R, Epperson CN, et al. Subtypespecific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004; 61 (7): 705-13 (Pubitemid 38890805)
43. Yildiz-Yesiloglu A, Ankerst DP. Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30 (6): 969-95 (Pubitemid 43928209)
44. Yuksel C, Ongur D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry 2010; 68 (9): 785-94
45. Salvadore G, Zarate CA Jr. Magnetic resonance spectroscopy studies of the glutamatergic system in mood disorders: a pathway to diagnosis, novel therapeutics, and personalized medicine? Biol Psychiatry 2010 Nov 1; 68 (9): 780-2
46. Gorman JM, Docherty JP. A hypothesized role for dendritic remodeling in the etiology of mood and anxiety disorders. J Neuropsychiatry Clin Neurosci 2010; 22 (3): 256-64
47. Holmes A, Wellman CL. Stress-induced prefrontal reorganization and executive dysfunction in rodents. Neurosci Biobehav Rev 2009; 33 (6): 773-83
48. McEwen BS. Stress, sex, and neural adaptation to a changing environment: mechanisms of neuronal remodeling. Ann N Y Acad Sci 2010; 1204 Suppl.: E38-59
49. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008; 33 (1): 88-109 (Pubitemid 350191319)
50. Lee LJ, Lo FS, Erzurumlu RS.NMDAreceptor-dependent regulation of axonal and dendritic branching. J Neurosci 2005; 25 (9): 2304-11
51. Bessa JM, Ferreira D, Melo I, et al. The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol Psychiatry 2009; 14 (8): 764-73, 739
52. Ongur D, Haddad S, Prescot AP, et al. Relationship between genetic variation in the glutaminase gene GLS1 and brain glutamine/glutamate ratio measured in vivo. Biol Psychiatry 2011; 70 (2): 169-74
53. Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012; 62 (1): 63-77
54. Manji HK, Quiroz JA, Sporn J, et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003; 53 (8): 707-42 (Pubitemid 39658487)
55. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010; 67 (8): 793-802
56. Zarate Jr CA, Brutsche NE, IbrahimL, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012; 71 (11): 939-46
57. Zarate Jr CA, Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006; 163 (1): 153-5 (Pubitemid 43050119)
58. Anand A, Gunn AD, Barkay G, et al. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a doubleblind, randomized, placebo-controlled trial. Bipolar Disord 2012; 14 (1): 64-70
59. Lenze EJ, Skidmore ER, Begley AE, et al. Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study. Int J Geriatr Psychiatry. Epub 2011 Dec 16
60. Mathew SJ, Murrough JW, aan het Rot M, et al. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 2010; 13 (1): 71-82
61. Ibrahim L, Diazgranados N, Franco-Chaves J, et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs. add-on riluzole: results from a four-week, double-blind, placebo-controlled study. Neuropsychopharmacology 2012May; 37 (6): 1526-33
62. Preskorn SH, Baker B, Kolluri S, et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-Daspartate antagonist, CP-101,606, in patients with treatmentrefractory major depressive disorder. JClin Psychopharmacol 2008; 28 (6): 631-7
63. Ibrahim L, DiazGranados N, Jolkovsky L, et al. A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. Neuropsychopharmacology 2012 May; 37 (6): 1526-33
64. Machado-Vieira R, Manji HK, Zarate CA. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 2009; 15 (5): 525-39
65. Lesch KP, Schmitt A. Antidepressants and gene expression profiling: how to SNARE novel drug targets. Pharmacogenomics J 2002; 2 (6): 346-8 (Pubitemid 36175796)
66. Meloni D, Gambarana C, De Montis MG, et al. Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats. Pharmacol Biochem Behav 1993; 46 (2): 423-6
67. Papp M, Moryl E. Antidepressant activity of noncompetitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol 1994; 263 (1-2): 1-7 (Pubitemid 24290246)
68. Layer RT, Popik P, Olds T, et al. Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715). Pharmacol Biochem Behav 1995; 52 (3): 621-7
69. Przegalinski E, Tatarczynska E, Deren-Wesolek A, et al. Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist. Neuropharmacology 1997; 36 (1): 31-7 (Pubitemid 27115840)
70. Nowak G, Trullas R, Layer RT, et al. Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J Pharmacol Exp Ther 1993; 265 (3): 1380-6 (Pubitemid 23321045)
71. Paul IA, Layer RT, Skolnick P, et al. Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine. Eur J Pharmacol 1993; 247 (3): 305-11
72. Paul IA, Nowak G, Layer RT, et al. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther 1994; 269 (1): 95-102 (Pubitemid 24143240)
73. Chaturvedi HK, Chandra D, Bapna JS. Interaction between N-methyl-D-aspartate receptor antagonists and imipramine in shock-induced depression. Indian J Exp Biol 1999; 37 (10): 952-8 (Pubitemid 29482158)
74. Machado-Vieira R, Salvadore G, Ibrahim LA, et al. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr Pharm Des 2009; 15 (14): 1595-611
75. Sanacora G, Zarate CA, Krystal JH, et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008; 7 (5): 426-37 (Pubitemid 351619114)
76. Malinow R, Malenka RC. AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci 2002; 25: 103-26 (Pubitemid 34748013)
77. Zhu JJ, Qin Y, Zhao M, et al. Ras and Rap control AMPA receptor trafficking during synaptic plasticity. Cell 2002; 110 (4): 443-55 (Pubitemid 35232288)
78. Esteban JA. AMPA receptor trafficking: a road map for synaptic plasticity. Mol Interv 2003; 3 (7): 375-85
79. Anggono V, Huganir RL. Regulation of AMPA receptor trafficking and synaptic plasticity. Curr Opin Neurobiol. Epub 2012 Jan 2
80. Bleakman D, Alt A, Witkin JM. AMPA receptors in the therapeutic management of depression. CNS Neurol Disord Drug Targets 2007; 6 (2): 117-26 (Pubitemid 46681772)
81. Chourbaji S, Vogt MA, Fumagalli F, et al. AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression. FASEB J 2008; 22 (9): 3129-34
82. Gibbons AS, Brooks L, Scarr E, et al. AMPA receptor expression is increased post-mortem samples of the anterior cingulate from subjects with major depressive disorder. J Affect Disord 2012 Feb; 136 (3): 1232-7
83. Maeng S, Zarate Jr CA, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5- methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008; 63 (4): 349-52 (Pubitemid 351146651)
84. Zarate Jr C, Machado-Vieira R, Henter I, et al. Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry 2010; 18 (5): 293-303
85. Alt A, Nisenbaum ES, Bleakman D, et al. A role for AMPA receptors in mood disorders. Biochem Pharmacol 2006; 71 (9): 1273-88
86. O'Neill MJ, Witkin JM. AMPA receptor potentiators: application for depression and Parkinson's disease. Curr Drug Targets 2007; 8 (5): 603-20 (Pubitemid 46794920)
87. Bleakman D, Lodge D. Neuropharmacology of AMPA and kainate receptors. Neuropharmacology 1998; 37 (10-11): 1187-204 (Pubitemid 28511275)
88. Borges K, Dingledine R. AMPA receptors: molecular and functional diversity. Prog Brain Res 1998; 116: 153-70 (Pubitemid 28526934)
89. Li X, Tizzano JP, Griffey K, et al. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 2001; 40 (8): 1028-33 (Pubitemid 32530609)
90. Knapp RJ, Goldenberg R, Shuck C, et al. Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur J Pharmacol 2002; 440 (1): 27-35 (Pubitemid 34312035)
91. Lindholm JS, Autio H, Vesa L, et al. The antidepressantlike effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf/heterozygous null mice. Neuropharmacology 2012; 62 (1): 391-7
92. Bursi R, Erdemli G, Campbell R, et al. Translational PK-PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576. Psychopharmacology (Berl) 2011; 218 (4): 713-24
93. Niciu MJ, Kelmendi B, Sanacora G. Overview of glutamatergic neurotransmission in the nervous system. Pharmacol Biochem Behav 2012; 100 (4): 656-64
94. Szewczyk B, Palucha-Poniewiera A, Poleszak E, et al. Investigational NMDA receptor modulators for depression. Expert Opin Investig Drugs 2012; 21 (1): 91-102
95. Krystal JH, Mathew SJ, D'Souza DC, et al. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs 2010; 24 (8): 669-93
96. Harrison NL, Simmonds MA. Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br J Pharmacol 1985; 84 (2): 381-91 (Pubitemid 15169227)
97. Bolshakov KV, Gmiro VE, Tikhonov DB, et al. Determinants of trapping block of N-methyl-d-aspartate receptor channels. J Neurochem 2003; 87 (1): 56-65 (Pubitemid 37210639)
98. Narita M, Yoshizawa K, Nomura M, et al. Role of the NMDA receptor subunit in the expression of the discriminative stimulus effect induced by ketamine. Eur J Pharmacol 2001; 423 (1): 41-6 (Pubitemid 32595726)
99. De Vry J, Jentzsch KR. Role of theNMDAreceptor NR2B subunit in the discriminative stimulus effects of ketamine. Behav Pharmacol 2003; 14 (3): 229-35 (Pubitemid 36735156)
100. Maler JM, Esselmann H, Wiltfang J, et al. Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons. Brain Res 2005; 1052 (2): 156-62 (Pubitemid 41116773)
101. Maeng S, Zarate Jr CA. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep 2007; 9 (6): 467-74 (Pubitemid 350284937)
102. Engin E, Treit D, Dickson CT. Anxiolytic-and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models. Neuroscience 2009; 161 (2): 359-69
103. Garcia LS, Comim CM, Valvassori SS, et al. Chronic administration of ketamine elicits antidepressant-like effects in rats without affecting hippocampal brain-derived neurotrophic factor protein levels. Basic Clin Pharmacol Toxicol 2008; 103 (6): 502-6
104. Garcia LS, Comim CM, Valvassori SS, et al. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32 (1): 140-4
105. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329 (5994): 959-64
106. Yilmaz A, Schulz D, Aksoy A, et al. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav 2002; 71 (1-2): 341-4
107. Garcia LS, Comim CM, Valvassori SS, et al. Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33 (3): 450-5
108. Li N, Liu RJ, Dwyer JM, et al. Glutamate N-methyl-Daspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 2011; 69 (8): 754-61
109. da Silva FC, do Carmo de Oliveira Cito M, da Silva MI, et al. Behavioral alterations and pro-oxidant effect of a single ketamine administration to mice. Brain Res Bull 2010; 83 (1-2): 9-15
110. Rosa AO, Lin J, Calixto JB, et al. Involvement of NMDA receptors and L-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice. Behav Brain Res 2003; 144 (1-2): 87-93 (Pubitemid 37011169)
111. Kos T, Popik P, Pietraszek M, et al. Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by ketamine in rats and mice. Eur Neuropsychopharmacol 2006; 16 (4): 297-310
112. Chindo BA, Adzu B, Yahaya TA, et al. Ketamineenhanced immobility in forced swim test: a possible animal model for negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2012; 26: 26
113. Moghaddam B, Adams B, Verma A, et al. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17 (8): 2921-7 (Pubitemid 27155025)
114. Green SM, Rothrock SG, Lynch EL, et al. Intramuscular ketamine for pediatric sedation in the emergency department: safety profile in 1022 cases. Ann Emerg Med 1998; 31 (6): 688-97 (Pubitemid 28252623)
115. Howes MC. Ketamine for paediatric sedation/analgesia in the emergency department. Emerg Med J 2004; 21 (3): 275-80 (Pubitemid 38585099)
116. Strayer RJ, Nelson LS. Adverse events associated with ketamine for procedural sedation in adults. Am J Emerg Med 2008; 26 (9): 985-1028
117. Jevtovic-Todorovic V, Wozniak DF, Benshoff ND, et al. A comparative evaluation of the neurotoxic properties of ketamine and nitrous oxide. Brain Res 2001; 895 (1-2): 264-7 (Pubitemid 32231166)
118. Valentine GW, Mason GF, Gomez R, et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res 2011; 191 (2): 122-7
119. Bunney BG, Bunney WE. Rapid-acting antidepressant strategies: mechanisms of action. Int J Neuropsychopharmacol 2011; 7: 1-19
120. aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010; 67 (2): 139-45
121. Phelps LE, Brutsche N, Moral JR, et al. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry 2009; 65 (2): 181-4
122. Price RB, Nock MK, Charney DS, et al. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009; 66 (5): 522-6
123. DiazGranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010; 71 (12): 1605-11
124. Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 2011; 14 (8): 1127-31
125. Mathew SJ, Shah A, Lapidus K, et al. Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs 2012; 26 (3): 189-204
126. Doble A. The pharmacology and mechanism of action of riluzole. Neurology 1996; 47 (6 Suppl. 4): S233-41 (Pubitemid 26422576)
127. Du J, Suzuki K, Wei Y, et al. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 2007; 32 (4): 793-802 (Pubitemid 46426179)
128. Mizuta I, Ohta M, Ohta K, et al. Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci Lett 2001; 310 (2-3): 117-20 (Pubitemid 32822818)
129. Zarate CA, Manji HK. Riluzole in psychiatry: a systematic review of the literature. Expert Opin Drug Metab Toxicol 2008; 4 (9): 1223-34
130. Papazisis G, et al. Neuroprotection by lamotrigine in a rat model of neonatal hypoxic-ischaemic encephalopathy. Int J Neuropsychopharmacol 2008; 11 (3): 321-9 (Pubitemid 351482501)
131. Goodnick PJ. Bipolar depression: a review of randomised clinical trials. Expert Opin Pharmacother 2007; 8 (1): 13-21 (Pubitemid 46070825)
132. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009; 194 (1): 4-9
133. Anand A, Charney DS, Oren DA, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-Daspartate receptor antagonists. Arch Gen Psychiatry 2000; 57 (3): 270-6 (Pubitemid 30140436)
134. Wang M, Yang Y, Dong Z, et al. NR2B-containing Nmethyl-D-aspartate subtype glutamate receptors regulate the acute stress effect on hippocampal long-term potentiation/long-term depression in vivo. Neuroreport 2006; 17 (12): 1343-6 (Pubitemid 44337079)
135. Loftis JM, Janowsky A. The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol Ther 2003; 97 (1): 55-85 (Pubitemid 35477804)
136. Gogas KR. Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr Opin Pharmacol 2006; 6 (1): 68-74 (Pubitemid 43103821)
137. Merchant RE, Bullock MR, Carmack CA, et al. A doubleblind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury. Ann N Y Acad Sci 1999; 890: 42-50 (Pubitemid 30040363)
138. Faries D, Herrera J, Rayamajhi J, et al. The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res 2000; 34 (1): 3-10 (Pubitemid 30006935)
139. Kemp AH, Gordon E, Rush AJ, et al. Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. CNS Spectr 2008; 13 (12): 1066-86; quiz 1087-8
140. Kornhuber J, Weller M, Schoppmeyer K, et al. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 1994; 43: 91-104 (Pubitemid 24362365)
141. Bormann J. Memantine is a potent blocker of N-methyl-Daspartate (NMDA) receptor channels. Eur J Pharmacol 1989; 166 (3): 591-2 (Pubitemid 19195356)
142. Kornhuber J, Bormann J, Retz W, et al. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortemhuman frontal cortex. Eur J Pharmacol 1989; 166 (3): 589-90 (Pubitemid 19195355)
143. Kornhuber J, Bormann J, Hubers M, et al. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 1991; 206 (4): 297-300
144. Kornhuber J, Weller M. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 1997; 41 (2): 135-44 (Pubitemid 27062653)
145. Muller WE, Mutschler E, Riederer P. Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Pharmacopsychiatry 1995; 28 (4): 113-24
146. Lo D, Grossberg GT. Use of memantine for the treatment of dementia. Expert Rev Neurother 2011; 11 (10): 1359-70
147. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology 1999; 38 (6): 735-67 (Pubitemid 29187336)
148. Tsai GE. Searching for rational anti N-methyl-D-aspartate treatment for depression. Arch Gen Psychiatry, 2007; 64 (9): 1099-100; author reply 1100-1 (Pubitemid 47360860)
149. Muhonen LH, Lonnqvist J, Juva K, et al. Double-blind, randomized comparison of memantine and escitalopram for the treatment ofmajor depressive disorder comorbid with alcohol dependence. J Clin Psychiatry 2008; 69 (3): 392-9 (Pubitemid 351549391)
150. Holter SM, Danysz W, Spanagel R. Evidence for alcohol anti-craving properties of memantine. Eur J Pharmacol 1996; 314 (3): R1-2 (Pubitemid 26382447)
151. Bachteler D, Economidou D, Danysz W, et al. The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat. Neuropsychopharmacology 2005; 30 (6): 1104-10 (Pubitemid 40720968)
152. Piasecki J, Koros E, Dyr W, et al. Ethanol-reinforced behaviour in the rat: effects of uncompetitive NMDA receptor antagonist, memantine. Eur J Pharmacol 1998; 354 (2-3): 135-43 (Pubitemid 28401445)
153. Escher T, Call SB, Blaha CD, et al. Behavioral effects of aminoadamantane class NMDA receptor antagonists on schedule-induced alcohol and self-administration of water in mice. Psychopharmacology (Berl) 2006; 187 (4): 424-34 (Pubitemid 44200514)
154. Boden JM, Fergusson DM. Alcohol and depression. Addiction 2011; 106 (5): 906-14
155. Conner KR, Pinquart M, Gamble SA. Meta-analysis of depression and substance use among individuals with alcohol use disorders. J Subst Abuse Treat 2009; 37 (2): 127-37
156. Nagy J. Renaissance of NMDA receptor antagonists: do they have a role in the pharmacotherapy for alcoholism? IDrugs 2004; 7 (4): 339-50
157. Petrakis IL, Limoncelli D, Gueorguieve R, et al. Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. Am J Psychiatry 2004; 161 (10): 1776-82 (Pubitemid 39314670)
158. Backstro P, Bachteler D, Koch S, et al. mGluR5 antagonist MPEP reduces ethanol-seeking and relapse behavior. Neuropsychopharmacology 2004; 29 (5): 921-8 (Pubitemid 38526792)
159. Krupitsky EM, Rudenko AA, Burakov AM, et al. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res 2007; 31 (4): 604-11 (Pubitemid 46434897)
160. Rogoz Z, Skuza G, Maj J, et al. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology 2002; 42 (8): 1024-30 (Pubitemid 34790257)
161. Huber TJ, Dietrich DE, Emrich HM. Possible use of amantadine in depression. Pharmacopsychiatry 1999; 32 (2): 47-55 (Pubitemid 29197549)
162. Rogoz Z, Kubera M, Rogoz K, et al. Effect of coadministration of fluoxetine and amantadine on immunoendocrine parameters in rats subjected to a forced swimming test. Pharmacol Rep 2009; 61 (6): 1050-60
163. Kubera M, Basta-Kairn A, Budziszewska B, et al. Effect of amantadine and imipramine on immunological parameters of rats subjected to a forced swimming test. Int J Neuropsychopharmacol 2006; 9 (3): 297-305 (Pubitemid 43780497)
164. Maj J, Rogoz Z. Synergistic effect of amantadine and imipramine in the forced swimming test. Pol J Pharmacol 2000; 52 (2): 111-4 (Pubitemid 30311781)
165. Dietrich DE, Bode L, Spannhuth CW, et al. Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial. Bipolar Disord 2000; 2 (1): 65-70
166. Ferszt R, Kuhl KP, Bode L, et al. Amantadine revisited: an open trial of amantadinesulfate treatment in chronically depressed patients with Borna disease virus infection. Pharmacopsychiatry 1999; 32 (4): 142-7 (Pubitemid 29434280)
167. Stryjer R, Strous RD, Shaked G, et al. Amantadine as augmentation therapy in the management of treatmentresistant depression. Int Clin Psychopharmacol 2003; 18 (2): 93-6 (Pubitemid 36343978)
168. Rogoz Z, Skuza G, Daniel WA, et al. Amantadine as an additive treatment in patients suffering from drugresistant unipolar depression. Pharmacol Rep 2007; 59 (6): 778-84 (Pubitemid 351586572)
169. Autry AE, Adachi M, Nosyreva E, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011; 475 (7354): 91-5
170. Hoeffer CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci 2010; 33 (2): 67-75
171. Duman RS, Li N, Liu RJ, et al. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012; 62 (1): 35-41
172. Cryan JF, O'Leary OF. Neuroscience: a glutamate pathway to faster-acting antidepressants? Science 2010; 329 (5994): 913-4
173. Ravikumar B, Rubinsztein DC. Can autophagy protect against neurodegeneration caused by aggregate-prone proteins? Neuroreport 2004; 15 (16): 2443-5 (Pubitemid 39579328)
174. Pickford F, Masliah E, Brtischgi M, et al. The autophagyrelated protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest 2008; 118 (6): 2190-9 (Pubitemid 351872337)
175. Beurel E, Song L, Jope RS. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry 2011; 16 (11): 1068-70
176. Kaidanovich-BeilinO, Milman A, Weizman A, et al. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry 2004; 55 (8): 781-4 (Pubitemid 38429867)
177. O'Brien WT, Harper AD, Jove F, et al. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 2004; 24 (30): 6791-8 (Pubitemid 38993901)
178. Beaulieu JM, Sotnikova TD, Yao WD, et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA. 2004; 101 (14): 5099-104 (Pubitemid 38469209)
179. Gould TD, Chen G, Manji HK. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 2004; 29 (1): 32-8 (Pubitemid 38068011)
180. Polter A, Beurel E, Yang S, et al. Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology 2010; 35 (8): 1761-74
181. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004; 29 (2): 95-102 (Pubitemid 38186580)
182. Rayasam GV, Tulasi VK, Sodhi R, et al. Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 2009; 156 (6): 885-98
183. Shimizu E, Hashimoto K, Iyo M. Ethnic difference of the BDNF 196G/A (val66met) polymorphism frequencies: the possibility to explain ethnic mental traits. Am J Med Genet B Neuropsychiatr Genet 2004; 126B (1): 122-3 (Pubitemid 38420134)
184. Casey BJ, Glatt CE, Tottenham N, et al. Brain-derived neurotrophic factor as a model system for examining gene by environment interactions across development. Neuroscience 2009; 164 (1): 108-20
185. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112 (2): 257-69 (Pubitemid 36144114)
186. Neves-Pereira M, Mundo E, Muglia P, et al. The brainderived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am J Hum Genet 2002; 71 (3): 651-5 (Pubitemid 34970137)
187. Sklar P, Gabriel SB, McInnis MG, et al. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neutrophic factor. Mol Psychiatry 2002; 7 (6): 579-93
188. Sen S, Nesse RM, Stoltenberg SF, et al. A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. Neuropsychopharmacology 2003; 28 (2): 397-401
189. Ribases M, Gratacò s M, Fernadez-Aranda F, et al. Association of BDNF with anorexia, bulimia and age of onset of weight loss in six European populations. Hum Mol Genet 2004; 13 (12): 1205-12 (Pubitemid 38877873)
190. Sun M, Liu L, Yang Y, et al. Association study of brainderived neurotrophic factor Val66Met polymorphism and clinical characteristics of first episode schizophrenia [in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2012; 29 (2): 155-8
191. Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 2012; 64 (2): 238-58
192. Machado-Vieira R, Yuan P, Brutsche N, et al. Brainderived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry 2009; 70 (12): 1662-6
193. Ricci V, Martinotti G, Gelfo F, et al. Chronic ketamine use increases serum levels of brain-derived neurotrophic factor. Psychopharmacology (Berl) 2011; 215 (1): 143-8
194. Inamura N, Nawa H, Takei N. Enhancement of translation elongation in neurons by brain-derived neurotrophic factor: implications for mammalian target of rapamycin signaling. J Neurochem 2005; 95 (5): 1438-45 (Pubitemid 41779267)
195. Slipczuk L, Bekinschtein P, Katche C, et al. BDNF activates mTOR to regulate GluR1 expression required for memory formation. PLoS ONE 2009; 4 (6): e6007
196. Takei N, Inamura N, Kawamura M, et al. Brain-derived neurotrophic factor induces mammalian target of rapamycin-dependent local activation of translation machinery and protein synthesis in neuronal dendrites. J Neurosci 2004; 24 (44): 9760-9 (Pubitemid 39463557)
197. Laje G, Lally N, Mathews D, et al. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry. In press
198. Liu RJ, Lee FS, Li XY, et al. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketaminestimulated synaptogenesis in prefrontal cortex. Biol Psychiatry 2012; 71 (11): 996-1005
199. Murrough JW. Ketamine as a novel antidepressant: from synapse to behavior. Clin Pharmacol Ther 2012; 91 (2): 303-9
200. Cornwell BR, Salvadore G, Furey M, et al. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry. Epub 2012 Apr 20
201. Li X, Witkin JM, Need AB, et al. Enhancement of antidepressant potency by a potentiator of AMPA receptors. Cell Mol Neurobiol 2003; 23 (3): 419-30 (Pubitemid 36676283)
202. Maes M, Bosmans E, Suy E, et al. Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology 1990; 24 (3): 115-20
203. Maes M, Bosmans E, Suy E, et al. Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiatr Scand 1991; 84 (4): 379-86
204. Maes M, Lambrechts J, Bosmans E, et al. Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychol Med 1992; 22 (1): 45-53
205. Bufalino C, Hepgul N, Aguglia E, et al. The role of immune genes in the association between depression and inflammation: a review of recent clinical studies. Brain Behav Immun. Epub 2012 May 8
206. Eyre H, Baune BT. Neuroplastic changes in depression: a role for the immune system. Psychoneuroendocrinology. Epub 2012 Apr 21
207. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59 (12): 1116-27
208. Catena-Dell'Osso M, Bellantuono C, Consoli G, et al. Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development? Curr Med Chem 2011; 18 (2): 245-55
209. Gardner A, Boles RG. Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35 (3): 730-43
210. Maes M, et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009; 24 (1): 27-53
211. Leonard B, Maes M. Mechanistic explanations how cellmediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012; 36 (2): 764-85
212. Moir AT, Eccleston D. The effects of precursor loading in the cerebral metabolism of 5-hydroxyindoles. J Neurochem 1968; 15 (10): 1093-108
213. Maes M, Leonard BE, Myint AM, et al. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35 (3): 702-21
214. Muller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 2007; 12 (11): 988-1000 (Pubitemid 350006207)
215. Moylan S, Maes M, Wray NR, et al. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry. Epub 2012 Apr 24
216. Koga K, Ogata M, Takenaka I, et al. Ketamine suppresses tumor necrosis factor-alpha activity and mortality in carrageenan-sensitized endotoxin shock model. Circ Shock 1994; 44 (3): 160-8
217. Taniguchi T, Shibata K, Yamamoto K. Ketamine inhibits endotoxin-induced shock in rats. Anesthesiology 2001; 95 (4): 928-32 (Pubitemid 32939117)
218. Taniguchi T, Takemoto Y, Kanakura H, et al. The doserelated effects of ketamine on mortality and cytokine responses to endotoxin-induced shock in rats. Anesth Analg 2003; 97 (6): 1769-72 (Pubitemid 37475136)
219. Suliburk JW, Helmer KS, Gonzalez EA, et al. Ketamine attenuates liver injury attributed to endotoxemia: role of cyclooxygenase-2. Surgery 2005; 138 (2): 134-40 (Pubitemid 41253793)
220. Welters ID, Hafer G, Menzebach A, et al. Ketamine inhibits transcription factors activator protein 1 and nuclear factor-kappaB, interleukin-8 production, as well as CD11b and CD16 expression: studies in human leukocytes and leukocytic cell lines. Anesth Analg 2010; 110 (3): 934-41
221. Albensi BC, Mattson MP. Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse 2000; 35 (2): 151-9 (Pubitemid 30036192)
222. Gutierrez H, Davies AM. Regulation of neural process growth, elaboration and structural plasticity by NFkappaB. Trends Neurosci 2011; 34 (6): 316-25
223. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27: 693-733
224. Roytblat L, Talmor D, Rachinsky M, et al. Ketamine attenuates the interleukin-6 response after cardiopulmonary bypass. Anesth Analg 1998; 87 (2): 266-71 (Pubitemid 28369075)
225. Bartoc C, Frumento RJ, Jalbout M, et al. A randomized, double-blind, placebo-controlled study assessing the antiinflammatory effects of ketamine in cardiac surgical patients. J Cardiothorac Vasc Anesth 2006; 20 (2): 217-22
226. Cho JE, Shim JK, Choi YS, et al. Effect of low-dose ketamine on inflammatory response in off-pump coronary artery bypass graft surgery. Br J Anaesth 2009; 102 (1): 23-8
227. Carlson PJ, Singh JB, Zarate Jr CA, et al. Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx 2006; 3 (1): 22-41 (Pubitemid 43279517)
228. Javitt DC, Schoepp D, Kalivas PW, et al. Translating glutamate: from pathophysiology to treatment. Sci Transl Med 2011; 3 (102): 102mr2
229. Orloff J, Douglas F, Pinheiro J, et al. The future of drug development: advancing clinical trial design. Nat Rev Drug Discov 2009; 8 (12): 949-57